Clinical Trials
8 trialsNCT07618390 2026-06-01
A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT07570966 2026-05-06
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Phase 1/2 Not yet recruiting
NCT07393321 2026-02-06
A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 3 Not yet recruiting
NCT07235618 2025-11-19
A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07163481 2025-09-16
SoGreat
Hunan Cancer Hospital
Phase 1 Not yet recruiting
NCT06929325 2025-04-16
Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Not yet recruiting
NCT06561022 2024-08-19
abemaSNF1/3
Fudan University
Phase 2 Not yet recruiting
NCT05986071 2024-03-29
MATRIX
Institut Paoli-Calmettes
Phase 1/2 Not yet recruiting